Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia?
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology*; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D002315:Cardiopulmonary Bypass; D002648:Child; D002675:Child, Preschool; D005240:Feasibility Studies; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D013923:Thromboembolism / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*
D001323:Autoantibodies; D006493:Heparin